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Abstract: Few adequately designed clinical trials have addressed optimal treatment duration 
in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharma-
codynamic proﬁ les may obtain early bacterial eradication allowing shorter treatment duration. 
This may be associated with a number of advantages including reduced resistance induction, 
increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g 
single dose of azithromycin microspheres has been compared with 7-day levoﬂ oxacin 500 mg 
or extended release clarithromycin in over 400 patients with community-acquired pneumonia. 
Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar 
between azithromycin and comparators. Azithromycin 2.0 g microspheres proved as effective 
as 7 days of levoﬂ oxacin 500 mg in acute exacerbation of chronic bronchitis patients across all 
degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical 
cure in most patients harbouring macrolide-resistant Streptococcus pneumoniae strains. The 
drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory 
adverse events. An undoubted advantage of single-dose azithromycin administration is the facility 
in ensuring that patients complete their prescribed course of therapy. A further advantage of 
single-dose therapy is the potential for use as directly-observed therapy, which may be useful 
in speciﬁ c clinical conditions.
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Introduction
The last 50 years have witnessed an impressive evolution in the antibiotic armamen-
tarium at the clinician’s disposal. The availability of effective antibiotic treatment has 
substantially impacted on overall mortality of patients with lower respiratory tract infec-
tions (LRTIs). International guideline drafting and implementation have been important 
in highlighting key factors in improving care in community-acquired pneumonia (CAP) 
and acute exacerbation of chronic bronchitis (AECB) (Woodhead et al 2005; Mandell 
et al 2007). Remarkably, guidelines contain few indications regarding the appropriate 
duration of antibiotic therapy. This reﬂ ects the paucity of appropriately designed large 
scale clinical trials addressing such an important treatment issue. Conventionally, 
antibiotics are continued until clinical and laboratory indices of infection are normal 
in patients with LRTIs. It is recognized that patients tend to interupt treatment once 
they feel better, decreasing compliance to treatment after that time point.
Antibiotic exposure is unavoidably associated with the phenomenon of antibiotic 
resistance due to a selection pressure on bacterial strains with natural or acquired 
resistance. Ideally, antibiotics should be maintained only up until bacteria are effectively 
cleared as further protraction of therapy increases unnecessary bacterial exposure 
to drugs. Currently, antimicrobial resistance is a global problem resulting in high 
hospitalization rates, mortality and costs in LRTIs (Sahm 2003). It has been suggested 
that shortening antimicrobial treatment duration may beneﬁ t resistance patterns. 
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For example, low dose and prolonged duration of β-lactam 
antibiotic treatment may contribute to promoting pharyn-
geal carriage of drug-resistant Streptococcus pneumoniae 
(Guillemot et al 1998), whereas high-dose short course amoxi-
cillin may be associated with signiﬁ cantly lower penicillin-
resistant S. pneumoniae carriage (Schrag et al 2001).
Patient adherence to prescribed antibiotic regimens is 
affected by variables including dosing interval, treatment 
duration, adverse effects, and palatability in pediatric 
patients. Adherence to once-daily regimens has been shown 
to be far superior to that of twice- (Kardas 2007) or thrice-
daily dosing schemes (Claxton et al 2001). It is fairly well 
established that patient compliance with antibiotic therapy 
begins to drop after 3–7 days of treatment (Kardas 2002). 
Additional potential benefits of short course antibiotic 
therapy in LRTIs patients include diminished impact on 
human endogenous ﬂ ora, decreased total drug exposure 
with reduced side effects, reduced health care worker time 
expenditure, and reduced costs.
In order to avoid falling short of effectively controlling 
infection, short-course antibiotic therapy should be based on 
robust pharmacokinetic and pharmacodynamic considerations. 
Candidate drugs for short-course regimens should be able to 
achieve adequate tissue penetrations and concentrations at 
the site of infection for a sufﬁ ciently long length of time to 
ensure bacterial eradication (Nicolau 2001). The development 
of an effective short course regimen requires a concentration-
dependent antimicrobial effect. The rate and extent of bacterial 
killing increase with increasing drug concentrations. For such 
agents the pharmacodynamic/pharmacokinetic predictors of 
efﬁ cacy are the area under the concentration-time curve/MIC 





treatment in lower respiratory
tract infections
Azithromycin is an azalide antibiotic exerting activity against 
most pathogens commonly involved in LRTIs. It acts by 
interfering with bacterial protein synthesis through binding 
of the 50S ribosomal subunit of susceptible microorgan-
isms. Azithromycin is an ideal candidate for short-course 
antibiotic regimens for a number of reasons. Compared 
with earlier macrolides, azithromycin shows improved 
pharmacokinetic/dynamic properties that determine a pro-
longed half-life and excellent tissue penetration. The drug 
rapidly moves from the bloodstream into the interstitial 
compartment resulting in low serum concentrations but high 
and persistent tissue concentrations (Amsden et al 1997). 
Characteristically, azithromycin concentration in lung tissue 
may be over a 100-fold greater than in the circulation. High 
tissue concentrations are maintained for extended periods of 
time due to slow release. Considering that respiratory tract 
infections reside in the interstitial space, tissue accumulation 
of azithromycin may guarantee high drug concentrations 
in the active site of infection. A further interesting charac-
teristic is the ability of azithromycin to concentrate within 
inﬂ ammatory cells, particularly neutrophils and monocytes 
within the bloodstream, and tissue macrophages (Mandell 
et al 2001). The ongoing inﬂ ammatory process in the lung 
recalls azithromycin-laden neutrophils from the circulation 
which then unload the drug in the presence of bacteria 
within inﬂ ammation sites (Hand et al 2001). Inﬂ ammatory 
cells therefore act as a “Trojan horse” delivering local 
concentrations of azithromycin that are several orders of 
magnitude greater than that in plasma. Neutrophil unloading 
and the extended half life of azithromycin (~60 hours) sus-
tain therapeutic drug concentrations at the site of infection 
for prolonged periods of time (Blumer 2005). Furthermore, 
inﬂ ammatory cell uptake of azithromycin is non-saturable 
and concentration dependent, suggesting that administration 
of higher doses of the drug early in the course of the infection 
may result in even greater drug concentration at the sites of 
infection.
Short-course treatment of CAP patients with azithromy-
cin has been shown to be effective, with the 3-day (500 mg 
single daily dose) regimen and the 5-day (500 mg ﬁ rst day, 
250 mg following days) regimens obtaining comparable 
results (Socan 1998). Clinical studies have shown that a 
3-day or 5-day treatment with azithromycin is at least as 
effective as more prolonged regimens of benzylpenicillin 
or erythromycin (Bohte et al 1995), and clarithromycin 
(O’Doherty et al 1998). Azithromycin and comparators 
were similar in terms of clinical, microbiological, and 
radiological results in outpatient or hospitalized cases of 
mild-to moderate CAP. Similarly, 3 or 5-day azithromycin 
regimens were clinically and microbiologically as effective 
as more prolonged treatment with amoxicillin-clavulanic 
acid (Hoepelman et al 1997), levoﬂ oxacin (Amsden et al 
2003), clarithromycin (Bradbury et al 1993) or 5-day 
courses of moxiﬂ oxacin (DeAbate et al 2000) or dirithro-
mycin (Castaldo et al 2003) in patients with AECB. Table 1 
shows a summary of clinical data for the quoted studies on 
azithromycin versus comparators in LRTIs.
Given its prolonged half-life, propensity to accumulate 
in tissues and inﬂ ammatory cells, and post antibiotic effect, 
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attempts have been made to condense conventional treatment 
into single large dose schemes of azithromycin (1.5 g in 
adults, 30 mg/kg in children) for the management of LRTIs. 
Administration of a single, higher dose of azithromycin 
has been shown to achieve more rapid bacterial eradication 
and enhanced survival than the same dose divided over 
several days in pre-clinical infection models of otitis media, 
murine pneumonia and septicemia (Girard et al 2005, Babl 
et al 2002). This suggests that antibiotic “front-loading”, 
attaining higher systemic exposure early in the course of 
infection (ie, the AUC from time zero to 24 hours [AUC
0–24
] 
post dosing), may result in more rapid and efﬁ cient bacterial 
clearance following the single-dose regimen. This may offer 
beneﬁ ts in terms of minimizing emergence of resistance.
In an open randomized study, the efﬁ cacy and safety of a 
single 1.5 g oral dose of azithromycin was compared with the 
standard 3-day regimen in the treatment of 100 patients with 
community-acquired atypical pneumonia (Schönwald et al 
1999). Clinical success was obtained in 97.9% of patients 
in both groups. Side effects were observed in 2 patients in 
the single-dose group, and one patient in the 3-day group. 
Due to the relatively small number of patients studied, the 
safety evaluation of the single-dose regimen is inconclusive. 
However, the study does indicate that a single 1.5 g dose 
of azithromycin may be an alternative to the standard 3-day 
azithromycin regimen in the treatment of outpatients with 
atypical pneumonia syndrome. A later study analyzed the 
serum and white blood cell pharmacokinetic behavior of 1.5 g 
single dose azithromycin compared to the same dose over 
3 days (Amsden et al 2001). The single drug bolus resulted 
in signiﬁ cantly higher peak serum concentration compared to 
the 3-day regimen, although the subjects’ overall drug expo-
sure did not differ signiﬁ cantly. At 10 days from the start of 
therapy both regimens showed intracellular white blood cell 
concentrations that were above the MIC
90
 values of the vast 
majority of community-acquired respiratory pathogens.
The highest single oral dose of azithromycin currently 
approved is an immediate-release 2.0 g sachet formulation 
of oral powder for suspension in the treatment of chlamydial 
and gonococcal urethritis and cervicitis (Handsﬁ eld et al 
1994). The reported 34% incidence of nausea and 14% 
incidence of diarrhea indicate that this formulation is likely 




Recently, microspheres have been developed as a means of 
effectively delivering antibiotics in periodontal (Paquette 
2007) and ocular diseases (Pijls et al 2006), for minimizing 
toxicity of antimycobacterial treatment (Rastogi et al 2006), 
and as an aid in Helicobacter pylori eradication (Patel et al 
2007). A novel azithromycin microsphere formulation 
(recently approved as Zmax in the USA) has been devel-
oped to address the challenge of administering a higher 
oral dose of the drug as a single dose while maintaining 
Table 1 Clinical success rates in studies evaluating azithromycin against comparators in the treatment of lower respiratory tract 
infections
First author, Setting Azithromycin Comparator/s No. of treated Clinical success
year  dosing scheme dosing scheme patients rate
Bohte 1995 CAP 500 mg once daily, 3 days Benzylpenicillin i.v. 35 azitromycin vs Azithromycin 83% vs
   Erythromycin 29 benzylpenicillin Benzylpenicillin 66%
    19 azithromycin vs Azithromycin 79% vs
    21 erythromycin Erythromycin 76% 
O’Doherty 1998 CAP 500 mg once daily, 3 days Clarithromycin 250 mg 101 azithromycin Azithromycin 94%
   twice daily, 10 days 102 clarithromycin Clarithromycin 95%
Bradbury 1993 LRTI 500 mg once daily, 3 days Clarithromycin 250 mg 252 azithromycin Azithromycin 94%
   twice daily, 10 days 258 clarithromycin Clarithromycin 97%
Hoepelman 1997 LRTI 500 mg once daily, 3 days Amoxi/clav acid 625 mg 62 azithromycin Azithromycin 95%
   3 times daily, 10 days 61 amoxi/clav acid Amoxi/clav 90%
DeAbate 2000 AECB 500 mg day 1, 250 mg  Moxifl oxacin 400 mg 243 azithromycin Azithromycin 92%
  days 2–5 once daily, 5 days 221 moxifl oxacin Moxifl oxacin 90%
Amsden 2003 AECB 500 mg day 1, 250 mg  Levofl oxacin 500 mg 118 azithromycin Azithromycin 89%
  days 2–5 once daily, 7 days 117 levofl oxacin Levofl oxacin 92%
Castaldo 2003 AECB 500 mg day 1, 250 mg Dirithromycin 500 mg 46 azithromycin Azithromycin 86.5%
  days 2–5 once daily, 5 days 40 dirithromycin Dirithromycin 95.5%
Abbreviations: CAP, community-acquired pneumonia; LRTI, lower respiratory tract infections; AECB, acute exacerbations of chronic bronchitis; Amoxi/clav, amoxicillin/
clavulanic acid.
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tolerability. The characteristics of the microspheres, with a 
mean diameter ranging from approximately 100–300 μm, 
were selected based on a combination of palatability, 
release profile, and manufacturability. Azithromycin is 
released slowly via diffusion through pores formed in-situ 
in the microspheres. Alkalinizing agents (sodium phosphate 
tribasic and magnesium hydroxide) were incorporated 
in the formulation. Following ingestion, the alkaline nature of 
the microsphere formulation delays initial release of drug in 
the stomach. Azithromycin is thus released over 2 hours after 
ingestion in the small intestine. This allows by-passing of 
the motilin receptors in the upper gastrointestinal tract. Local 
drug activation of the motilin receptors is thought to mediate 
much of the macrolide-related gastrointestinal side effects 
(Takeshita et al 2006). Motilin receptor density is maximal 
in the antrum and decreases in the aboral direction. All the 
drug is released prior to the colon, thus ensuring maximal 
bioavailability (approximately 83%) (Chandra et al 2007). In 
an open-label, randomized, parallel-group study of 24 healthy 
adult subjects the pharmacokinetic proﬁ les of azithromycin 
given as 2.0 g microspheres were characterized in serum 
and white blood cells and compared with those of a 3-day 
regimen totaling 1.5 g (Liu et al 2007). Compared with the 
conventional 3-day 1.5 g azithromycin treatment, the single-
dose 2.0 g microsphere formulation obtained a 2-fold higher 
maximum plasma concentration (C
max
) and a 3-fold higher 
24-hour area under the concentration-time curve (AUC
0–24
) 
at day 1. The total systemic exposure in serum over 5 days 
following the start of dosing (AUC
0–120
) was similar for the 
two regimens. Similarly, in white blood cells, threefold 
higher drug exposure and maximal concentrations were found 
at day 1 following single dose administration compared with 
the 3-day regimen.
In an observer-blind, parallel group, single-dose study, 
the tolerability proﬁ les of azithromycin 2.0 g microspheres 
were compared with the immediate-release azithromycin 2.0 g 
sachet formulation of oral powder for suspension (Chandra 
et al 2007). This was a complex study that also evaluated 
pharmacokinetic proﬁ les of the two compounds and the effect 
of food (high fat meal and a standard meal) and an antiacid on 
the rate of drug absorption. A total of 377 healthy male and 
female volunteers were recruited. Compared with the sachet 
oral powder suspension, the microsphere formulation was 
associated with a slower absorption rate (57% decrease in 
mean C
max
 with a 2.5 hour delay in time to reach C
max
). How-
ever, because the AUC values were comparable, overall drug 
exposure was similar. The incidence of gastrointestinal side 
effects (abdominal pain, nausea, vomiting, and diarrhea) was 
signiﬁ cantly lower with azithromycin microspheres compared 
to the immediate-release formulation. One non-gastrointestinal 
adverse event common to azithromycin slow-release and imme-
diate release was headache (12% and 6%, respectively). In both 
groups over 90% of adverse events were mild in intensity and 
occurred within the ﬁ rst 2 hours after dosing. Both the high fat 
meal and the standard meal increased the rate of drug absorp-
tion (2-fold higher C
max
 values, and 2- to 4-hour shortening of 
time to maximal concentration) but were associated with an 
increased incidence of nausea and vomiting. It was assumed 
that meal-triggered gastric acid secretions led to faster release 
of azithromycin from the microspheres (Chandra et al 2007). 
Because of the decreased tolerability of the formulation when 
taken with food, it was suggested that azithromycin micro-
spheres be taken on an empty stomach. Pharmacokinetic prop-
erties of the azithromycin microspheres were not signiﬁ cantly 
affected by co-administration of an antiacid.
Azithromycin microspheres
in community-acquired pneumonia
Two phase III multinational, multicenter, double-blind, 
double-dummy studies analyzed the efﬁ cacy and safety of a 
new microsphere (MS) formulation of azithromycin, 2.0 g 
given as a single dose, compared with either the extended-
release formulation of clarithromycin) (1 g od for 7 days) 
(Drehobl et al 2005) or with levoﬂ oxacin (500 mg od for 
7 days) (D’Ignazio et al 2005) in the treatment of adults with 
mild-to-moderate CAP.
In the clarithromycin extended-release comparator trial, 
eligible subjects were required to be 16 years of age or older, 
with cough productive of sputum and a diagnosis of pneumo-
nia as demonstrated by two or more of the following signs or 
symptoms: auscultatory ﬁ ndings on pulmonary examination 
of rales and/or evidence of pulmonary consolidation; dyspnea 
or tachypnea; body temperature 38 °C (oral); or an elevated 
total peripheral white blood cell count (10,000/mm3) 
or 15% immature neutrophils (bands). In addition, subjects 
had to have a prospectively calculated Modiﬁ ed Fine Risk 
score of ~70 (Fine Classes I and II) (Fine et al 1997). A total 
of 501 subjects were randomized and 499 were treated. 
Patients were recruited at 58 centers in 7 countries among 
the US, Canada, Europe, and Asia. In the levoﬂ oxacin trial, 
subjects were aged 18 years or older with a clinical diagnosis 
of mild-to-moderate CAP with a Fine mortality risk class 
of I, II, or III (ie, a risk score of ~90). In total, 427 patients 
were randomized, of whom 423 received study medication. 
Patients were enrolled at 56 centers in 8 countries among 
North and South America, Europe, and Asia.
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In both studies, clinical assessments were conducted at 
baseline (Day 1), during treatment (Days 3–5), at the end 
of treatment (Days 8–11), post treatment at the test of cure 
(TOC) visit (Days 14–21) and at a long-term follow-up visit 
(Days 28–35). Clinical efﬁ cacy was assessed at the TOC 
visit. Subjects with a clinical response of cure at the TOC 
visit were assessed for relapse at the long-term follow-up visit 
(Days 28–35). Bacteriological response was assessed in those 
subjects from whom a pathogen was identiﬁ ed at baseline. 
Table 2 shows the demographics and baseline characteristics 
of the patients enrolled in the two studies. No differences in 
terms of either clinical response or bacteriological response 
were noted between azithromycin microspheres and 
comparators at the TOC visit (Days 14–21) (Table 3).
In the azithromycin vs clarithromycin study, at the 
long-term follow-up visit (days 28–35), only 1 subject 
(0.6%) in the azalide study arm and 5 subjects (2.8%) in the 
clarithromycin study arm were classiﬁ ed as having relapsed. 
Clinical cure rates in patients with multilobar pneumonia 
were only slightly lower than those in patients with single 
lobe pneumonia (88.5% vs 94.4%). Two azithromycin-
treated subjects and one clarithromycin-treated subject 
were hospitalized for worsening of pneumonia. In this study 
there were 4 deaths, all of which were in the clarithromycin 
extended release arm. None of the deaths were attributed to 
study therapy or progression of CAP. In the study comparing 
azithromycin microspheres with levoﬂ oxacin, 6 subjects 
(2 azithromycin and 4 levoﬂ oxacin) were hospitalized for 
worsening pneumonia; 2 of the levoﬂ oxacin-treated and 1 of 
the azithromycin-treated subjects ultimately died of causes 
other than pneumonia.
In the azithromycin vs clarithromycin study a pathogen 
was identiﬁ ed in 281/499 (56%) of treated patients, with 
evidence of mixed infection in 16%. An atypical pathogen 
was identiﬁ ed in 24% of azithromycin-treated subjects. 
In the azithromycin vs levoﬂ oxacin study a pathogenic 
microrganism was identiﬁ ed in 219/423 (52%) of treated 
patients, a mixed infection being present in 11%. Atypical 
pneumonia was identiﬁ ed in 27% of the azithromycin arm 
cases. Data on S. pneumoniae eradication rates and clinical 
response, according to bacterial susceptibility to macrolides 
and penicillin, were analyzed in both studies (Tables 4 and 5). 
No clear relationship between resistance patterns and clinical 
and bacteriological outcomes was observed. In the two studies 
combined, 13 azithromycin-resistant S. pneumoniae strains 
were found, 7 of which were treated with azithromycin, with 
clinical cure and bacteriological eradication (presumed or 
documented) being obtained in 4/7.
Macrolide-resistant pneumococci are increasing world-
wide (Gay et al 2000). However, the clinical signiﬁ cance of 
this ﬁ nding is still debated as resistance has been associated 
with clinical failure in some (Fogarty et al 2000) but not all 
studies (Aspa et al 2004). Particularly, treatment failure is 
not unusual in cases of bacteremic pneumococcal pneumonia 
(Lonks 2002), although most clinical failures showed 
underlying conditions that would have contraindicated 
the empirical choice of a macrolide as ﬁ rst line treatment. 
As mentioned above, the administration of a single high 
dose of azithromycin is likely to result in concentrations 
of azithromycin in lung tissue and ﬂ uids that would be 
effective against S. pneumoniae with low-level macrolide 
resistance.
The safety and tolerability of this novel azithromycin 
formulation were excellent. The majority of all reported 
adverse events were mild or moderate in severity. For 
azithromycin microspheres, most adverse events occurred on 
the day of administration and resolved within 2 days. There 
were no clinically signiﬁ cant changes in clinical laboratory 
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Table 2 Demographics and baseline characteristics of patients included in two comparative phase III community-acquired pneumonia 
studies of 2 g single-dose azithromycin microspheres (D’Ignazio et al 2005; Drehobl et al 2005)
 Drehobl et al 2005   D’Ignazio et al 2005
 Azithromycin Clarithromycin Azithromycin Levofl oxacin 
 microspheres XL 1.0 g microspheres 500 mg
 (n = 247) (n = 252) (n = 211) (n = 212)
Mean age (years) 45.6 43.6 48.2 49.0
No. of subjects 65 years (%) 32 (13%) 26 (10.3%) 49 (23.2%) 48 (22.6%)
Male/female 112/135 134/118 121/90 109/103
History of diabetes 13 11 20 27
Unilobar disease 211 219 172 181
Smoker/ex-smoker 131 139 99 100
Abbreviation: XL, extended release.
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parameters. Table 6 shows the adverse reactions recorded 
in the two studies. In both studies, the azithromycin group 
showed a greater number of diarrhea and loose stools adverse 
events. In most cases the effect was limited to the day of 
therapy or the following day.
Owing to the single-dose nature of the regimen, all 
azithromycin-treated patients completed the treatment 
course, whereas 15 of 254 subjects (5.9%) randomized 
to the clarithromycin XL arm did not complete the 
entire 7-day course of active treatment and 10 of the 212 
levoﬂ oxacin-treated subjects (4.7%) did not complete the 
full 7-day treatment course.
The results of these controlled trials in CAP demon-
strated that a single 2.0 g dose of azithromycin microspheres 
is at least as effective as a 7-day treatment with either 
clarithromycin extended release or levoﬂ oxacin, conﬁ rming 
the suitability of the new formulation of azithromycin.
Azithromycin microspheres in acute 
exacerbations of chronic bronchitis
Proper management of an AECB should result in rapid 
resolution of the acute episode and decrease in the likelihood 
of treatment failure and of an early recurrence (Martinez 2005). 
The role of antibiotic treatment in AECB is less straightfor-
ward than in CAP. It is felt that only approximately 50% of 
exacerbations are sustained by bacteria (Monso et al 1995) 
and the issue is complicated by the fact that approximately 
25%–40% of COPD patients present stable bacterial coloni-
zation of the airways outside periods of acute deterioration 
(Cabello et al 1997). Attempts have been made to identify 
patients more likely to present bacterial aetiology of an 
exacerbation based on the presence of at least 2 out of 3 of 
the clinical Anthonisen criteria (increased cough, increased 
in sputum production, change in sputum color) (Anthonisen 
et al 1987). Among the three symptoms, sputum purulence 
has been most strongly associated with bacterial exacerbation 
(Stockley et al 2000; Allegra et al 2005). Additionally, 
patient baseline severity must also be considered as antibi-
otics have a greater beneﬁ cial effect in patients with more 
severe disease (Allegra et al 2001), which translates into a 
survival advantage in those sufﬁ ciently severe to require 
mechanical ventilation (Nouira et al 2001). Regrettably, in 
most older antibiotic efﬁ cacy studies on patients with exacer-
bations a precise deﬁ nition of COPD was often absent, with 
enrolment of young, non-obstructed never-smokers, unsatis-
factory deﬁ nitions of exacerbation, high population severity 
heterogeneity, and lacked stratiﬁ cation for steroid use.
A recent double-blind, double-dummy study com-
pared azithromycin microspheres (2 g single dose) with 
levoﬂ oxacin (500 mg once daily for 7 days) in patients with 
AECB (Zervos et al 2005). Patients were clearly deﬁ ned 
with stratiﬁ cation for the use of systemic steroids, and 
strict inclusion and exclusion criteria. A total of 551 sub-
jects were randomized and 438 were treated at 62 centers 
in 13 countries. Most enrolled subjects were advanced-age 
patients with a past history of smoking, documented airﬂ ow 
Table 3 Clinical and bacteriological response rates at days 14-21 in two studies comparing azithromycin 2.0 g microspheres 
with either extended release clarithromycin or levofl oxacin in patients with community-acquired pneumonia (D’Ignazio et al 2005; 
Drehobl et al 2005)
 Drehobl et al 2005  D’Ignazio et al 2005
 Azithromycin Clarithromycin Azithromycin Levofl oxacin
 microspheres XL 1.0 g microspheres 500 mg 
Clinical response 92.6% (n = 202) 94.7% (n = 209) 89.7% (n = 174) 93.7% (n = 209)
Bacteriological response 93.0% (n = 100) 92.1 (n = 127) 90.1% (n = 91) 92.3% (n = 104)
Clinical response by pathogen     
  Haemophilus infl uenzae 14/15 (93%)  23/26 (88%) 14/15 (93%) 8/8 (100%)
  Moraxella catarrhalis 8/8 (100%) 3/5 (60%) 7/7 (100%) 2/2 (100%)
  Streptoccoccus pneumoniae 17/19 (89%) 25/27 (93%) 11/14 (79%) 10/12 (83%)
  Chlamydia pneumoniae 19/21 (90%) 29/31 (94%) 18/19 (94%) 21/22 (95%)
  Mycoplasma pneumoniae 25/26 (96%) 20/21 (95%) 5/7 (71%) 18/18 (100%)
Abbreviation: XL, extended release.
Table 4 Antimicrobial susceptibility of the 56 Streptococcus 
pneumioniae isolates identifi ed in the study comparing azithro-
mycin 2.0 g microspheres with extended release clarithromycin 
(Drehobl et al 2005)
 Susceptible Intermediate Resistant
Penicillin 38 (68%) 16 (29%) 2 (4%)
Azithromycin 49 (88%) 1 (2%) 6a (11%)
Clarithromycin 50 (89%) 0 6 (11%)
a2/6 among azithromycin-treated patients.
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obstruction, at least one AECB in the previous year, and 
presented all three cardinal Anthonisen symptoms in the 
current exacerbation. Patient baseline demographic char-
acteristics are shown in Table 7.
The clinical cure rate at the test-of-cure (TOC) visit (Days 
14–21) in the treated population was comparable between the 
two agents (93.6% for azithromycin compared with 92.7% 
for levoﬂ oxacin). Baseline microbiological testing yielded 
positive results in approximately 49% of subjects. In these 
patients, the overall bacteriological eradication rate was 
comparable between the two treatment regimens (91.9% for 
azithromycin versus 94.4% for levoﬂ oxacin).
Additional post hoc analyses of the 272 subjects in 
this study with spirometric evidence of airway obstruction 
suggests equal efficacy of azithromycin microspheres 
compared with levofloxacin across all strata of COPD 
severity using the GOLD and ATS/ERS stratification 
schemes (Pauwels et al 2001; Celli et al 2004) (Table 8). 
The majority of enrolled patients presented advanced disease 
severity. During the course of the trial and the follow-up 
period, 12 patients needed hospitalization. Eight of these 
occurred in the levoﬂ oxacin-treated arm while 4 occurred 
in azithromycin microsphere-treated patients. There was no 
clear pattern noted, although the majority of hospitalized 
patients had more severe airway obstruction at baseline.
Among the patients treated with azithromycin microspheres, 
5 were found to harbor macrolide-resistant S. pneumoniae 
strains. All patients were reported as clinically cured. In 1 patient 
with the highest macrolide MIC values (256 μg/mL), persis-
tence of the baseline pathogen was established at the 10-day 
TOC visit despite clinical resolution of the acute symptoms.
Conclusions
Optimal duration for antimicrobial treatment in lower 
respiratory tract infections (LRTIs) is still undetermined. 
Short-course treatments may be a means for maintaining 
clinical efficacy while containing antibiotic resistance 
spread, increasing patient compliance, and limiting drug-
related adverse events. As recently pointed out by Thomas 
M. File (File 2004), the basic rationale behind short-course 
antibiotic treatment in CAP is to “hit hard and stop early”. 
Candidate drugs must show favorable pharmacokinetic and 
pharmacodynamic properties allowing high and prolonged 
antimicrobial concentrations at the site of infection.
The novel azithromycin microsphere formulation takes 
the concept of short-course treatment one step further by 
allowing single-dose antibiotic administration in LRTIs. 
Use of this formulation allows greater peak concentrations 
of the drug early in the course of infection with similar 
overall total antimicrobial exposure compared to traditional 
3- to 5-day dosing regimens. This may allow sufﬁ ciently 
high concentration to effectively eradicate even moderately 
resistant organisms. The results of controlled trials in CAP 
and COPD exacerbations demonstrate that a single dose of 
azithromycin microspheres is at least as effective and well 
tolerated as a 7-day treatment with either extended release 
clarithromycin or levoﬂ oxacin.
An undoubted advantage of single-dose azithromycin 
administration is the facility in ensuring that patients complete 
their prescribed course of therapy. Failure to complete 
Table 5 Antimicrobial susceptibility of the 28 Streptococcus 
pneumioniae isolates identifi ed in the study comparing azithro-
mycin 2.0 g microspheres with extended release clarithromycin 
(D’Ignazio et al 2005)
 Susceptible Intermediate Resistant
Penicillin 19 (68%) 8 (29%) 1 (4%)
Azithromycin 21 (75%) 0 7a (25%)
Levofl oxacin 28 (100%) 0 0
a5/7 among azithromycin-treated patients.
Table 6 Incidence of adverse events in two studies comparing azithromycin 2.0 g microspheres with either extended release 
clarithromycin or levofl oxacin in patients with community-acquired pneumonia (D’Ignazio et al 2005; Drehobl et al 2005)
 Drehobl et al 2005  D’Ignazio et al 2005
 Azithromycin Clarithromycin Azithromycin Levofl oxacin 
 microspheres (n = 247) XL 1.0 g (n = 252) microspheres (n = 211) 500 mg (n = 212)
Diarrhea/loose stools 30 (12.1%) 19 (7.5%) 27 (12.8%) 11 (5.2%)
Nausea 9 (3.6%) 8 (3.2%) 3 (1.4%) 2 (0.9%)
Abdominal pain 9 (3.6%) 3 (1.2%) 4 (1.9%) 2 (0.9%)
Rash 3 (1.2%) 1 (0.4%) 1 (0.5%) 0
Taste perversion 3 (1.2%) 9 (3.6%) 0 1 (0.5%)
Vomiting 2 (0.8%) 2 (0.8%) 4 (1.9%) 2 (0.9%)
Abbreviation: XL, extended release.
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therapy may be associated with deterioration in the patient’s 
condition, treatment failure, and increased use and cost of 
healthcare resources such as the requirement for additional 
drugs and hospital admission. Incomplete treatment may also 
increase the likelihood that bacteria will develop resistance. 
Another advantage of single-dose therapy is the potential for 
use as directly observed therapy (DOT). The use of a DOT 
in LRTIs is intriguing, particularly in congested clinical 
situations (such as emergency departments) where assuring 
patient compliance may be troublesome or barriers to ﬁ lling 
prescriptions may exist.
Predictably, such a form of treatment may encounter 
some resistance among interested parties. Physicians may be 
doubtful as to whether a single dose regimen may be reliable 
and effective for the treatment of their patients with LRTIs. 
Similarly, patients are accustomed to taking medications 
everyday while they are sick, with interruption of treatment 
often coinciding with symptom resolution. Clearly, further 
sound clinical demonstration of efﬁ cacy and recognition of 
patient subsets most likely to beneﬁ t are needed before wide-
spread use of this approach to LRTIs can be considered.
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